Q-omics provides the consensus-scored RPL26P19 profile across patient tissues and cancer cell-line models. RPL26P19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPL26P19 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RPL26P19 RNA expression shows 15,608 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, COAD, and ACC as cancer lineages where RPL26P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26P19 survival associations across molecular data types. RPL26P19 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26P19 RNA expression–survival associations across cancer types. High RPL26P19 expression shows unfavorable associations in ACC and KICH, but favorable associations in THCA, READ, SKCM and LUSC. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify THCA as the clearest survival context for RPL26P19 RNA expression.
This table summarizes RPL26P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL26P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26P19 shows lower tumor expression in BRCA and UCEC and higher tumor expression in COAD, KIRC, CHOL and THCA. The COAD box plot shows higher RPL26P19 RNA expression in tumor versus normal tissue (log2 FC = +0.819, t-test p = .001).
This table shows molecular features associated with RPL26P19 in patient tissues and cancer cell lines. In patient samples, RPL26P19 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
